La cadena de opciones muestra datos clave de las opciones de acciones de Theravance Biopharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Theravance Biopharma..

Theravance Biopharma (NASDAQ:TBPH) Bolsa, Cadena de Opciones

Theravance Biopharma

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADAP

ADTX

AREB

ATMV

BYND

CYCU

DCGO

GLPG

GSIT

HTCR

IBIO

JWEL

KXIN

NEUP

RYOJ

SONM

TBPH

El premercado muestra fuertes movimientos tras resultados mixtos, con CCK liderando las subidas y varios valores biotecnológicos en caída.

Acciones de Crown Holdings (CCK) suben un 9%; Aquí están 20 acciones que se mueven en el premercado

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma Inc

Press Releases

Theravance Biopharma to Participate in an Upcoming Investor Conference

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025

Earnings

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting

Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy

Alumis

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Canopy Growth Corporation - Common Shares

Canopy Growth

Cormedix

Cronos Group

Evolus

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

GH Research

LB Pharmaceuticals

LENZ Therapeutics

MBX Biosciences

Mind Medicine (MindMed) Inc. - Common Shares

Mind Medicine

Oculis Holding

Omeros

Pacira BioSciences

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Septerna

SIGA Technologies

SNDL

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Zevra Therapeutics

B. Riley Securities

BTIG

Jones Trading

HC Wainwright & Co.

TD Cowen

Comments

Theravance Biopharma

Theravance Biopharma (TBPH) Opciones

Theravance Biopharma (NASDAQ:TBPH) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL